STOCK TITAN

Madison Avenue Group Reports 9.7% Stake in SAGE (6.08M Shares)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Reporting Persons — Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha — disclosed beneficial ownership of 6,077,065 shares of Sage Therapeutics common stock, representing approximately 9.7% of the 62,620,694 shares used as the basis for the calculation. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power claimed.

The statement was filed on Schedule 13G, indicating a passive stake, and includes a certification that the securities were not acquired to change or influence control of the issuer.

Positive

  • Material disclosure of 6,077,065 shares (approximately 9.7% of the class), which provides transparency to the market
  • Filed on Schedule 13G, indicating the Reporting Persons represent a passive stake and include a certification they are not seeking to change control

Negative

  • None.

Insights

TL;DR A substantial passive position of 9.7% is disclosed, notable for size but presented as non-control.

The reported 6,077,065-share position is material relative to outstanding stock and is large enough to influence trading dynamics or trigger investor attention. The Schedule 13G form and the certification that the securities were not acquired to change control suggest the Reporting Persons intend a passive investment stance rather than activist engagement. For investors, the key implications are transparency of ownership and potential for market impact without an explicit governance agenda.

TL;DR Group ownership near 10% requires monitoring, but Schedule 13G filing signals passive intent and no declared control attempt.

The aggregated ownership by related entities and an individual highlights a connected ownership structure where Madison Avenue-affiliated entities and Eli Samaha are deemed beneficial owners. The filing discloses shared voting and dispositive power, not sole control. Governance risk is limited by the explicit certification denying control-seeking purposes, yet the economic stake remains significant and merits attention to any future amendments or Schedule 13D filings.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Madison Avenue Partners LP
Signature:s/ Eli Samaha
Name/Title:Eli Samaha, as Managing Member of EMAI Management, LLC, the General Partner of Madison Avenue Partners, LP
Date:08/14/2025
Madison Avenue International LP
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Manager of Madison Avenue GP, LLC, the General Partner of Madison Avenue International LP
Date:08/14/2025
EMAI Management, LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Managing Member
Date:08/01/2025
Madison Avenue GP, LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Manager
Date:08/14/2025
Caraway Jackson Investments LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Member
Date:08/14/2025
Eli Samaha
Signature:Eli Samaha
Name/Title:ELI SAMAHA
Date:08/14/2025

FAQ

Who filed the Schedule 13G/A for Sage Therapeutics (SAGE)?

The filing was made by Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha.

How many SAGE shares do the Reporting Persons beneficially own?

They reported beneficial ownership of 6,077,065 shares of Sage Therapeutics common stock.

What percentage of SAGE does the disclosed stake represent?

The position represents approximately 9.7% of the class, based on 62,620,694 shares used for the calculation.

Does the Schedule 13G/A indicate an intent to influence control of SAGE?

The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer, indicating a passive intent.

What voting and dispositive powers are reported for the stake?

The Reporting Persons report 0 sole voting and 0 sole dispositive power and 6,077,065 shared voting and shared dispositive power.
Sage Therapeutic

NASDAQ:SAGE

SAGE Rankings

SAGE Latest News

SAGE Latest SEC Filings

SAGE Stock Data

543.56M
56.11M
10.36%
83.6%
3.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE